How to improve the risk-benefit ratio of antidepressants
| Autor: | Corruble E, Puech Aj |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Risk analysis
Psychiatric Status Rating Scales medicine.medical_specialty Depressive Disorder Dose-Response Relationship Drug business.industry Poison control Suicide prevention Antidepressive Agents Drug Administration Schedule Surgery Psychiatry and Mental health Risk–benefit ratio Risk Factors Injury prevention medicine Anxiety Antidepressant Humans Pharmacology (medical) Drug Therapy Combination Onset of action medicine.symptom Intensive care medicine business |
| Zdroj: | International clinical psychopharmacology. 8(4) |
| ISSN: | 0268-1315 |
| Popis: | To improve the risk associated with present antidepressant drugs, it is necessary to choose drugs that are selective and well tolerated in overdose, to look for contraindications, to adapt the dose progressively, to inform and supervise patients adequately, and to deal with risks due to the main pharmacological effects (anxiety, nervousness, sleep disturbances, suicide). With new drugs, risk improvement will probably be the result of greater selectivity. Improvements in efficacy could emerge during the development of new drugs, based on the monoaminergic and non-monoaminergic hypotheses. Much progress could be made, however, by questioning present practices. Optimizing dose, duration of treatment, co-medication, strategies for non-responders, and compliance, decreasing onset of action and targeting patients may help improve the efficacy of present antidepressant drugs. Language: en |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|